Chordate Medical’s third quarter of 2023 marked the beginning of the autumn series of scientific congresses, where the company also launched the new brand Ozilia®, replacing K.O.S in all markets where the treatment is offered. The period began with a scientific poster presenting the results of the pivotal migraine study PM007 at the International Headache Congress in Seoul. Ozilia® was highlighted by several other speakers as a potential valuable treatment alternative when medication is not suitable or desired.
On Wednesday, November 1st, Chordate’s CEO Anders Weilandt presented the company’s Q3 report and provided information on the focus for the remainder of the year on Finwire TV. He also answered questions from viewers, discussing topics such as the global market for neurostimulation solutions, including Ozilia®.
“We belong to a large industry segment known as neurostimulation, and a significant amount of money is being invested in it. It also generates substantial revenue in the market. We belong to the chronic pain segment, with our two indications being a subset. This would help an observer understand that a significant amount of money is being invested in this segment by the industry. There is great interest, and it is growing rapidly in this industry segment. So, there is a strong focus from major industrial players globally.”
Anders Weilandt also talked about the importance of new treatment options like Ozilia® for migraine care.
“Every migraine specialist or neurologist has a toolbox that includes a variety of medications and alternatives. None of these existing treatment options work for more than half of the patients. And none of the existing drug alternatives work for a lifetime; they have an effect for a few years, then the effect starts to diminish, and a change in treatment is required for that reason. Or side effects emerge that the patient can no longer tolerate. Ozilia® is another alternative, and the lack of alternatives is a problem for healthcare and for patients.”
